NovaGo Raises $30M Series B to Advance Spinal Injury Drug Trial
Schlieren – September 07, 2026 -- NovaGo Therapeutics AG has closed a Series B financing round of CHF 24 million ($30 million), led by Neurimmune and Pureos, to fund a proof-of-concept trial for its anti-Nogo-A antibody in acute spinal cord injury.
The equity round drew participation from existing and new investors and was supplemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.
NovaGo to enroll 120 patients across Germany, Spain and Switzerland
Proceeds will push the company's lead program, NG004, into a fully randomized, double-blind proof-of-concept study recruiting 120 acute spinal cord injury patients at centers in the three countries. NG004 is a fully human antibody designed to block Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system.